Harmony Biosciences Holdings (HRMY) Cash from Financing Activities (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Cash from Financing Activities data on file, last reported at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 1950.57% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at -$15.9 million (down 106.31% YoY), and the FY2025 full-year result was -$9.0 million, up 17.71% from the prior year.
• Cash from Financing Activities slipped to -$7.2 million in Q1 2026, from -$3.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $3.4 million in Q1 2023 to a low of -$55.1 million in Q3 2023.
• A 5-year average of -$7.4 million and a median of -$2.7 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 11425.0% in 2022 and tumbled 2787.76% in 2023, its largest moves.
• Tracing HRMY's Cash from Financing Activities over 5 years: stood at $2.7 million in 2022, then plunged by 2113.66% to -$53.5 million in 2023, then surged by 94.88% to -$2.7 million in 2024, then slipped by 10.0% to -$3.0 million in 2025, then slumped by 139.4% to -$7.2 million in 2026.
• Business Quant data shows HRMY's Cash from Financing Activities at -$7.2 million in Q1 2026, -$3.0 million in Q4 2025, and -$3.0 million in Q3 2025.